News & Updates
Filter by Specialty:
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
First-line treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP1) receptor agonists improves outcomes in patients with type 2 diabetes (T2D), but to be cost-effective, the prices of these drugs must drop by at least 70 percent, suggests a study.
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
15 Oct 2022
Pemetrexed-based chemo boosts survival in NSCLC
As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.
Pemetrexed-based chemo boosts survival in NSCLC
15 Oct 2022
Pre-DAA IL-1β can predict HBV reactivation in HCV
Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.
Pre-DAA IL-1β can predict HBV reactivation in HCV
14 Oct 2022
DIY diabetes management with digital app facilitates better weight, blood sugar control
Self-management of diabetes through smartphone heath app engagement appears to bring positive changes in disease outcomes such as weight and blood sugar, according to data from the Diabetes Lifestyle Intervention using Technology Empowerment (D’LITE) study.
DIY diabetes management with digital app facilitates better weight, blood sugar control
14 Oct 2022
Maternal ultra-processed food intake ups risk of childhood obesity
Mothers who regularly eat ultra-processed foods during the child-rearing period appear to increase the risk of overweight or obesity in their children, irrespective of maternal and offspring lifestyle risk factors, a study has shown.